![Roche to Buy Bowel-Disease Drug From Roivant, Pfizer for More Than $7 Billion Roche to Buy Bowel-Disease Drug From Roivant, Pfizer for More Than $7 Billion](https://morningtopnews.com/wp-content/uploads/2023/10/1698104690_social-768x384.jpeg)
[ad_1]
Updated Oct. 23, 2023 6:55 am ET
Roche Holding has agreed to buy the developer of a bowel-disease treatment from Roivant Sciences, a company started by Republican presidential candidate Vivek Ramaswamy, and Pfizer in a deal worth more than $7 billion.
The Swiss pharmaceutical giant said Monday it would pay $7.1 billion upfront for Telavant Holdings, and make a near-term milestone payment of $150 million. Roche said the deal gives it rights to commercialize Telavant’s RVT-3101 drug candidate, which has shown promise for inflammatory-bowel disease and could have potential in other indications, in the U.S. and Japan.
Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
[ad_2]
Source link